Mount Sinai to host center of excellence for digital pathology

Digital pathology—and how artificial intelligence might support it—is expected to get a boost from a new center of excellence at a leading New York health system.

Two vendors—LabCorp and Philips—are collaborating with Mount Sinai Health System on the initiative, which will be called the Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence.

The new center will use the Philips IntelliSite Pathology Solution, the first digital pathology system approved by the Food and Drug Administration for primary diagnostic use, which many believe will help the organizations enhance the quality and lower the costs of patient care.

LabCorp will lead the integration of Philips’ system at Mount Sinai, leveraging its previous expertise with the digital pathology technology, which it implemented in four of its laboratories back in 2018.

Initially, Philips’ system will be used at Mount Sinai for interpretations of genitourinary malignancies, mainly prostate tumors, as well as cancers of the head and neck. The technology will enable Mount Sinai to expand its digital pathology capabilities for primary diagnosis and consultations across Mount Sinai’s system, improving collaboration among pathologists and making it easier to provide expert diagnostic opinions in complex cases.

Pathology-Philips-CROP.jpg

The center of excellence will be housed within Mount Sinai’s Department of Pathology, Molecular and Cell-Based Medicine. The department processes more than 80 million diagnostic tests a year, making it one of the largest academic departments of its kind in the country.

The center will be studying ways to incorporate digital imaging for pathology purposes and incorporating artificial intelligence to expand the potential for pathologists to make contributions to patient care.

Digital pathology will enable real-time pathology interpretations for physicians and patients throughout the New York metropolitan area without requiring pathologists to be on-site where the patient is receiving care.

“Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases,” says Carlos Cordon-Cardo, MD, chairman of the department of pathology, molecular and cell-based medicine at Mount Sinai, as well as professor of pathology, genetics and genomic sciences in oncological sciences at the Icahn School of Medicine at Mount Sinai.

“In addition to our new predictive AI-based tests, this introduces the potential for optimization of treatment efficacy and provides the opportunity for improved clinical outcomes,” he adds.

LabCorp plans to expand digital pathology capabilities to more of its laboratories in the coming year and is working with key partners such as Mount Sinai to help support their transition to digital pathology and AI.

For reprint and licensing requests for this article, click here.